EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Dual-view jointly learning improves personalized drug synergy prediction

Xueliang Li iD, Bihan Shen iD, Fangyoumin Feng iD, Kunshi Li, Zhixuan Tang, Liangxiao Ma iD, Hong Li iD

Bioinformatics · 2024

DOI: 10.1093/bioinformatics/btae604 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bioinformatics, 2024. Verfasst von Xueliang Li und 6 weiteren Autor:innen. Beteiligte Einrichtung: CAS Key Laboratory of Computational Biology, Shanghai Institute of Nutrition and Health, University of Chinese Academy of Sciences, Chinese Academy o…. Hauptthemen laut MEDLINE: Precision Medicine, Drug Synergism, Neoplasms. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Shanghai, CAS Youth Innovation Promotion Association.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Motivation Accurate and robust estimation of the synergistic drug combination is important for medicine precision. Although some computational methods have been developed, some predictions are still unreliable especially for the cross-dataset predictions, due to the complex mechanism of drug combinations and heterogeneity of cancer samples. Results We have proposed JointSyn that utilizes dual-view jointly learning to predict sample-specific effects of drug combination from drug and cell features. JointSyn outperforms existing state-of-the-art methods in predictive accuracy and robustness across various benchmarks. Each view of JointSyn captures drug synergy-related characteristics and makes complementary contributes to the final prediction of the drug combination. Moreover, JointSyn with fine-tuning improves its generalization ability to predict a novel drug combination or cancer sample using a small number of experimental measurements. We also used JointSyn to generate an estimated atlas of drug synergy for pan-cancer and explored the differential pattern among cancers. These results demonstrate the potential of JointSyn to predict drug synergy, supporting the development of personalized combinatorial therapies. Availability and implementation Source code and data are available at https://github.com/LiHongCSBLab/JointSyn.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Precision MedicineDrug SynergismNeoplasmsHumansComputational BiologyMachine LearningAntineoplastic AgentsAlgorithms

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • CAS Key Laboratory of Computational Biology, Shanghai Institute of Nutrition and Health, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai 200031, China.
  • Bio-Med Big Data Center, CAS Key Laboratory of Computational Biology, Shanghai Institute of Nutrition and Health, Chinese Academy of Science, Shanghai 200031, China.

ORCID-Profile: Xueliang Li, Bihan Shen, Fangyoumin Feng, Liangxiao Ma, Hong Li

Förderung

  • National Natural Science Foundation of China
  • Natural Science Foundation of Shanghai
  • CAS Youth Innovation Promotion Association

Zitieren

APA

Li, X., Shen, B., Feng, F., Li, K., Tang, Z., Ma, L., & Li, H. (2024). Dual-view jointly learning improves personalized drug synergy prediction. Bioinformatics. https://doi.org/10.1093/bioinformatics/btae604

Vancouver

Li X, Shen B, Feng F, Li K, Tang Z, Ma L, et al. Dual-view jointly learning improves personalized drug synergy prediction. Bioinformatics. 2024. doi:10.1093/bioinformatics/btae604

BibTeX
@article{Li2024,
  author = {Li, Xueliang and Shen, Bihan and Feng, Fangyoumin and Li, Kunshi and Tang, Zhixuan and Ma, Liangxiao and Li, Hong},
  title = {Dual-view jointly learning improves personalized drug synergy prediction},
  journal = {Bioinformatics},
  year = {2024},
  doi = {10.1093/bioinformatics/btae604}
}
Kostenlos starten →